US FDA submits new peptide compounding policy for White House review
by@Reuters
Summary
On October 15, the US FDA took a significant step by submitting a new policy change regarding peptide compounding to the White House for consideration, which could facilitate pharmacies in compounding certain peptides. This move follows recommendations from advisers to relax restrictions on several peptides, including the popular BPC-157, known for its purported benefits in pain relief and muscle recovery. Telehealth company Hims & Hers Health has shown interest in offering these peptides if regulations allow, highlighting the growing public attention and demand for such compounds promoted by influencers and officials, despite the fact that these peptides have not yet been approved by the FDA for safety or efficacy.
Tokens
$HIMS
Analysis
US FDA: The US Food and Drug Administration is the primary federal agency responsible for regulating the safety, efficacy, and security of drugs, biologics, and related products. It submitted an interim access policy for compounding certain peptides to the White House for review. The agency is overseeing the potential easing of restrictions on peptides following prior adviser input. Amina Niasse: Amina Niasse is a journalist contributing additional reporting from New York on the FDA peptide compounding developments. She supported coverage of the policy submission and industry context. Sahil Pandey: Sahil Pandey is a Reuters journalist based in Bengaluru who reported on the FDA's submission of the peptide policy change. His coverage details the filing and related responses from involved parties. Yasmeen Abutaleb: Yasmeen Abutaleb is a journalist providing additional reporting from Washington on the FDA and White House-related policy update. Her work helped detail the interagency submission process. Hims & Hers Health: Hims & Hers Health is a telehealth company focused on providing accessible health and wellness treatments through online platforms. It has expressed plans to offer certain peptides once regulations allow. The company is positioned to expand its services if the proposed FDA policy changes are approved. Robert F. Kennedy Jr.: Robert F. Kennedy Jr. serves as the Secretary of Health and Human Services. He has publicly promoted the use of peptides for various health applications. His position places him at the intersection of the agency's policy review process. Department of Health and Human Services: The Department of Health and Human Services is the federal cabinet department that oversees the FDA and public health policy. It collaborated with the FDA to submit the interim peptide compounding policy for White House consideration. The department manages broader health regulatory frameworks referenced in the development. Regulation: The FDA submitted an interim access policy for compounding certain peptides to the White House for review. Public Attention: Peptides have received promotion from social media influencers and senior health officials for uses such as recovery and wellness. Industry Interest: Telehealth providers are preparing to expand offerings of peptides if regulatory conditions change.
Categories
macropolitics